Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Antiangiogenic therapies for advanced hepatocellular carcinoma Sampat KR; O'Neil BOncologist 2013[]; 18 (4): 430-8Hepatocellular carcinoma (HCC) is a significant cause of death worldwide. HCC is a highly vascular tumor, and proangiogenic cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor may play crucial roles in this disease. Sorafenib, a multikinase inhibitor that blocks VEGF and PDGF signaling, was the first systemic therapy to demonstrate improved survival in patients with advanced HCC. Several other drugs targeting VEGF are in development. Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed.|Angiogenesis Inhibitors/*genetics/therapeutic use[MESH]|Carcinoma, Hepatocellular/drug therapy/*genetics/pathology[MESH]|Fibroblast Growth Factors/genetics/therapeutic use[MESH]|Humans[MESH]|Liver Neoplasms/drug therapy/*genetics/pathology[MESH]|Molecular Targeted Therapy[MESH]|Neovascularization, Pathologic/drug therapy/*genetics/pathology[MESH]|Niacinamide/analogs & derivatives/therapeutic use[MESH]|Phenylurea Compounds/therapeutic use[MESH]|Platelet-Derived Growth Factor/genetics/therapeutic use[MESH]|Sorafenib[MESH]|Vascular Endothelial Growth Factor A/*genetics/metabolism[MESH] |